Experimental Drug Shows Promise in Slowing Disability from Multiple Sclerosis
Results of a phase 3 clinical trial show an experimental drug called tolebrutinib can delay disability in patients with non-relapsing secondary progressive multiple sclerosis.
Health News is provided as a service to Creech & Gibbs Pharmacy site users by HealthDay. Creech & Gibbs Pharmacy nor its employees, agents, or contractors, review, control, or take responsibility for the content of these articles. Please seek medical advice directly from your pharmacist or physician.